The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year collaboration with Myoderm, a global leader and specialist in sourcing, distribution, and management of comparator drugs and other pharmaceutical products and supplies for clinical research. Myoderm will participate as a Global Impact Partner (GIP) and align with sponsors, CROs and other industry solution providers who share an ongoing commitment to promoting site sustainability across the clinical trials landscape.

“SCRS is pleased to welcome Myoderm as our newest Global Impact Partner,” comments Christine Pierre, SCRS President. “Collaboration with Myoderm will incite dialogue around drug and product sourcing for clinical trials. These factors can affect individual sites with the burden on extra staff resources. Myoderm has supply chain experience that factors into trial design, and can be shared to gain efficiencies in the processes currently being used.”

“We are honored to be a part of and collaborate with such an innovative organization and group of professionals,” Michael Cohen, Managing Director of Myoderm, remarks. “For more than 25 years we have focused on developing clinical trial supply solutions for sponsors, CROs and research sites alike. We see this partnership as an opportunity to make further advancements to the supply chain, alleviating pressure on research sites and positively impacting patients that benefit from new therapies being developed.”

As a Global Impact Partner (GIP), Myoderm will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.

About SCRS
SCRS is a global trade organization founded in 2012 which represents over 2,300 research sites, including 30,000 research professionals in 40 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites, as well as companies that sponsor or support the work conducted at clinical research sites, will benefit from membership and partnership. Visit

To learn more, contact us.

Print this content
download this content